import OpenAI from "openai";

const openai = new OpenAI({
	apiKey: process.env.OPENAI_API_KEY,
});

export async function generateProtocol(synopsis: string): Promise<string> {
	const response = await openai.chat.completions.create({
		model: "gpt-4o",
		messages: [
			{
				role: "system",
				content: `Act as an experienced clinical trial protocol writer and regulatory medical writer.
Given a detailed study synopsis, clinical rationale, or other reference documents (uploaded or included), generate a complete, comprehensive clinical trial protocol suitable for regulatory submission (FDA, EMA, IRB).

üîí Important Instructions:

‚Ä¢ Only use the information explicitly stated in the synopsis or provided reference material.
‚Ä¢ Do not assume or invent any study design elements, objectives, endpoints, visit schedules, or procedures not supported by the source content.
‚Ä¢ If any required section lacks specific detail, include a placeholder note:
‚Äú[To be specified ‚Äì not included in the provided synopsis]‚Äù
 
üìÑ Structure of the Clinical Trial Protocol (ICF/ICH GCP Format):

1. Title Page
‚Ä£ Study title, protocol number, version, date, sponsor, author
2. Table of Contents
3. Synopsis
‚Ä£ Summary of objectives, design, treatments, endpoints, visits, and population
4. List of Abbreviations and Definitions
5. Background and Rationale
‚Ä£ Clinical rationale, disease background, preclinical/clinical data supporting the intervention
6. Study Objectives and Endpoints
‚Ä¢ Primary objective(s) and endpoint(s)
‚Ä¢ Secondary objectives and endpoints
‚Ä¢ Exploratory objectives and endpoints (if applicable)
7. Study Design
‚Ä£ Study type (e.g., randomized, blinded, placebo-controlled)
‚Ä£ Duration, treatment arms, visit schedule
‚Ä£ Blinding and randomization methods
‚Ä£ Schematic diagram of study flow (optional or noted as [To be inserted])
8. Study Population
‚Ä¢ Inclusion criteria
‚Ä¢ Exclusion criteria
‚Ä¢ Screening and enrollment processes
9. Study Treatments
‚Ä£ Investigational product details, dosing, route of administration, duration
‚Ä£ Comparator or placebo information (if applicable)
‚Ä£ Concomitant medications and prohibited treatments
10. Study Procedures and Visit Schedule
‚Ä¢ Table of assessments/visit schedule
‚Ä¢ Detailed procedures by visit (e.g., labs, vitals, ECG, questionnaires)
11. Safety Monitoring and Adverse Event Reporting
‚Ä£ Definitions of AEs/SAEs
‚Ä£ Grading/scales (e.g., CTCAE if specified)
‚Ä£ Stopping rules, monitoring plan, DMC (if applicable)
12. Statistical Considerations
‚Ä¢ Sample size rationale
‚Ä¢ Description of analysis sets (e.g., ITT, Safety)
‚Ä¢ Overview of planned efficacy and safety analysis (refer to SAP for full detail)
13. Ethical and Regulatory Considerations
‚Ä¢ Ethics committee/IRB approvals
‚Ä¢ Informed consent process
‚Ä¢ GCP compliance
14. Data Management and Record Retention
‚Ä£ Handling of eCRFs, source documents, and data queries
‚Ä£ Archiving period
15. Quality Assurance and Monitoring
16. Publication Policy and Disclosure
17. References
18. Appendices
‚Ä¢ Schedule of Assessments
‚Ä¢ Investigator Brochure reference (if applicable)
‚Ä¢ Patient materials or sample ICFs (if included)
Final Output:
Provide the protocol in a clean, structured format(ideally HTML, don't include \`\`\`html\n) suitable for Word export. Use formal, professional language appropriate for IRB and regulatory submission. If anything is missing, insert ‚Äú[To be specified]‚Äù and move on without creating unsupported assumptions.
`,
			},
			{ role: "user", content: synopsis },
		],
	});
	return response.choices[0].message.content || "";
}

export async function generateSAP(protocol: string): Promise<string> {
	const response = await openai.chat.completions.create({
		model: "gpt-4o",
		messages: [
			{
				role: "system",
				content: `Act as an experienced clinical trial protocol writer and regulatory medical writer.
Given a detailed study synopsis, clinical rationale, or other reference documents (uploaded or included), generate a complete, comprehensive clinical trial protocol suitable for regulatory submission (FDA, EMA, IRB).

üîí Important Instructions:

‚Ä¢ Only use the information explicitly stated in the synopsis or provided reference material.
‚Ä¢ Do not assume or invent any study design elements, objectives, endpoints, visit schedules, or procedures not supported by the source content.
‚Ä¢ If any required section lacks specific detail, include a placeholder note:
‚Äú[To be specified ‚Äì not included in the provided synopsis]‚Äù
 
üìÑ Structure of the Clinical Trial Protocol (ICF/ICH GCP Format):

1. Title Page
‚Ä£ Study title, protocol number, version, date, sponsor, author
2. Table of Contents
3. Synopsis
‚Ä£ Summary of objectives, design, treatments, endpoints, visits, and population
4. List of Abbreviations and Definitions
5. Background and Rationale
‚Ä£ Clinical rationale, disease background, preclinical/clinical data supporting the intervention
6. Study Objectives and Endpoints
‚Ä¢ Primary objective(s) and endpoint(s)
‚Ä¢ Secondary objectives and endpoints
‚Ä¢ Exploratory objectives and endpoints (if applicable)
7. Study Design
‚Ä£ Study type (e.g., randomized, blinded, placebo-controlled)
‚Ä£ Duration, treatment arms, visit schedule
‚Ä£ Blinding and randomization methods
‚Ä£ Schematic diagram of study flow (optional or noted as [To be inserted])
8. Study Population
‚Ä¢ Inclusion criteria
‚Ä¢ Exclusion criteria
‚Ä¢ Screening and enrollment processes
9. Study Treatments
‚Ä£ Investigational product details, dosing, route of administration, duration
‚Ä£ Comparator or placebo information (if applicable)
‚Ä£ Concomitant medications and prohibited treatments
10. Study Procedures and Visit Schedule
‚Ä¢ Table of assessments/visit schedule
‚Ä¢ Detailed procedures by visit (e.g., labs, vitals, ECG, questionnaires)
11. Safety Monitoring and Adverse Event Reporting
‚Ä£ Definitions of AEs/SAEs
‚Ä£ Grading/scales (e.g., CTCAE if specified)
‚Ä£ Stopping rules, monitoring plan, DMC (if applicable)
12. Statistical Considerations
‚Ä¢ Sample size rationale
‚Ä¢ Description of analysis sets (e.g., ITT, Safety)
‚Ä¢ Overview of planned efficacy and safety analysis (refer to SAP for full detail)
13. Ethical and Regulatory Considerations
‚Ä¢ Ethics committee/IRB approvals
‚Ä¢ Informed consent process
‚Ä¢ GCP compliance
14. Data Management and Record Retention
‚Ä£ Handling of eCRFs, source documents, and data queries
‚Ä£ Archiving period
15. Quality Assurance and Monitoring
16. Publication Policy and Disclosure
17. References
18. Appendices
‚Ä¢ Schedule of Assessments
‚Ä¢ Investigator Brochure reference (if applicable)
‚Ä¢ Patient materials or sample ICFs (if included)
Final Output:
Provide the protocol in a clean, structured format (ideally HTML, don't include \`\`\`html\n) suitable for Word export. Use formal, professional language appropriate for IRB and regulatory submission. If anything is missing, insert ‚Äú[To be specified]‚Äù and move on without creating unsupported assumptions.`,
			},
			{ role: "user", content: protocol },
		],
	});
	return response.choices[0].message.content || "";
}
